Strep Throat Treatment Market (By Disease Type: Acute Strep Throat, Pharyngitis, Tonsillitis, Laryngitis, By Treatment Type: Antibiotics, Pain Relievers; By Diagnosis: Antibody Test, Physical Examination, Throat Culture; By Route Of Administration: Oral, Topical, Injectable; By End-use: Hospitals, Specialty Clinics, Diagnostic Laboratories; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Strep Throat Treatment Market
5.1. COVID-19 Landscape: Strep Throat Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Strep Throat Treatment Market, By Disease Type
8.1. Strep Throat Treatment Market, by Disease Type, 2024-2033
8.1.1. Acute Strep Throat
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pharyngitis
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Tonsillitis
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Laryngitis
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Strep Throat Treatment Market, By Treatment Type
9.1. Strep Throat Treatment Market, by Treatment Type, 2024-2033
9.1.1. Antibiotics
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Pain Relievers
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Strep Throat Treatment Market, By Diagnosis
10.1. Strep Throat Treatment Market, by Diagnosis, 2024-2033
10.1.1. Antibody Test
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Physical Examination
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Throat Culture
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Strep Throat Treatment Market, By Route Of Administration
11.1. Strep Throat Treatment Market, by Route Of Administration, 2024-2033
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Topical
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Injectable
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Strep Throat Treatment Market, By End-use
12.1. Strep Throat Treatment Market, by End-use, 2024-2033
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Specialty Clinics
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Diagnostic Laboratories
12.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Strep Throat Treatment Market, By Distribution Channel
13.1. Strep Throat Treatment Market, by Distribution Channel, 2024-2033
13.1.1. Hospital Pharmacy
13.1.1.1. Market Revenue and Forecast (2021-2033)
13.1.2. Retail Pharmacy
13.1.2.1. Market Revenue and Forecast (2021-2033)
13.1.3. Online Pharmacy
13.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 14. Global Strep Throat Treatment Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.1.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.1.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.1.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.1.5. Market Revenue and Forecast, by End-use (2021-2033)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.1.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.1.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.1.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.1.8. Market Revenue and Forecast, by End-use (2021-2033)
14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.1.9.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.1.9.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.1.9.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.1.10. Market Revenue and Forecast, by End-use (2021-2033)
14.1.11. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.2.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.2.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.2.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.2.5. Market Revenue and Forecast, by End-use (2021-2033)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.2.8.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.2.8.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.2.9. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.2.10. Market Revenue and Forecast, by End-use (2021-2033)
14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.2.11.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.2.11.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.2.12. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.2.13. Market Revenue and Forecast, by End-use (2021-2033)
14.2.14. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.2.15.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.2.15.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.2.15.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.2.16. Market Revenue and Forecast, by End-use (2021-2033)
14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.2.17.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.2.17.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.2.17.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.2.18. Market Revenue and Forecast, by End-use (2021-2033)
14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.3.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.3.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.3.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.3.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.3.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.3.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.3.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.3.8. Market Revenue and Forecast, by End-use (2021-2033)
14.3.9. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.3.10.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.3.10.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.3.10.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.3.11. Market Revenue and Forecast, by End-use (2021-2033)
14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.3.12.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.3.12.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.3.12.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.3.12.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.3.13.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.3.13.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.3.13.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.3.13.5. Market Revenue and Forecast, by End-use (2021-2033)
14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.4.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.4.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.4.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.4.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.4.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.4.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.4.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.4.8. Market Revenue and Forecast, by End-use (2021-2033)
14.4.9. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.4.10.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.4.10.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.4.10.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.4.11. Market Revenue and Forecast, by End-use (2021-2033)
14.4.12. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.4.13.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.4.13.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.4.13.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.4.13.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.4.14.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.4.14.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.4.14.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.4.14.5. Market Revenue and Forecast, by End-use (2021-2033)
14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.5.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.5.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.5.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.5.5. Market Revenue and Forecast, by End-use (2021-2033)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.5.7.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.5.7.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.5.7.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.5.8. Market Revenue and Forecast, by End-use (2021-2033)
14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2021-2033)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Disease Type (2021-2033)
14.5.9.2. Market Revenue and Forecast, by Treatment Type (2021-2033)
14.5.9.3. Market Revenue and Forecast, by Diagnosis (2021-2033)
14.5.9.4. Market Revenue and Forecast, by Route Of Administration (2021-2033)
14.5.9.5. Market Revenue and Forecast, by End-use (2021-2033)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 15. Company Profiles
15.1. Pfizer Inc.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. AstraZeneca
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Novartis AG
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Bayer AG
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. GSK Plc.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Amgen Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Merck & Co, Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Mitsubishi Chemical Group Corp.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Teva Pharmaceutical Industries Ltd.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client